Updates in the Treatment of HR+ Breast Cancer - Episode 8

Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

, , ,

A panel of experts discuss navigating 2L treatment strategies.

Video content above is prompted by the following:

  • What are your perceptions on efficacy and safety data on PROTAC
  • What are your perceptions on efficacy and safety data on SERM:
    • Lasoxifene: ASCO 2024 #TPS1127: Phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib
  • How do these options compare? Why might you choose one of these options vs fulvestrant?